

Resolutions of the Annual Shareholders' Meeting of Sartorius AG

- Annual Shareholders' Meeting passes resolution to pay dividends of 1.52 euros per preference share and 1.50 euros per ordinary share
- Approval of share capital increase by use of retained earnings for "stock split" of 4 for 1

Goettingen, April 7, 2016 – At today's Annual Shareholders' Meeting in Goettingen, Germany, shareholders approved the board's proposals by a large majority. The Annual Shareholders' Meeting thus passed the resolution to pay dividends of 1.52 euros per preference share (previous year: 1.08 euros) and 1.50 euros per ordinary share (previous year: 1.06 euros). The total amount disbursed will rise by 41.5% year over year from 18.2 million euros to 25.8 million euros.

In addition, the Annual Shareholders' Meeting approved a share capital increase by use of retained earnings for carrying out a so-called stock split. Every shareholder will receive three additional shares of the same type for every share held, which will automatically be registered by the end of May. The company's retained earnings will be converted for this "stock split" and, therefore, share capital will accordingly quadruple to 74,880,000 euros. Furthermore, for the preference shares, a surplus dividend of 0.01 euro per share and a minimum dividend of 0.02 euro per share were established. The Supervisory Board and the Executive Board had submitted a stock split proposal as the Sartorius share prices have risen to substantial three-digit figures over the past years.

The Annual Shareholders' Meeting granted discharge to the Supervisory Board and to the Executive Board by a considerable majority. On the whole, more than 400 share owners representing over 96% of the voting share capital attended this year's Annual Shareholders' Meeting.

Presentation Held by Dr. Joachim Kreuzburg at the Annual Shareholders' Meeting

You will find this presentation and further information on the ASM at:

www.sartorius.com/en/company/investor-relations/sartorius-ag/shareholders-meeting/2016/

Current Image Files

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG

www.sartorius.com/fileadmin/media/global/company/Sartorius_Kreuzburg.jpg

Sartorius products used in the manufacture of medications

www.sartorius.com/fileadmin/media/global/company/pr_20140303_bioprocess_solutions.jpg

Sartorius products used in laboratory research

www.sartorius.com/fileadmin/media/global/company/pr_20140303_lab_products_and_services.jpg

Upcoming Financial Dates

April 20, 2016	Publication of first-quarter figures (January to March 2016)
July 25, 2016	Publication of the first-half figures (January to June 2016)
October 24, 2016	Publication of nine-month figures (January to September 2016)

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

A Profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.1 billion euros in 2015. More than 6,200 people work for the Group, which has its own manufacturing and sales sites in around 110 countries.

Contract

Petra Kirchhoff, Vice President of Corporate Communications
+49 (0)551.308.1686 | petra.kirchhoff@sartorius.com